About: ANCA-Associated Renal Vasculitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ANCA-Associated Renal Vasculitis - An Update Goto Sponge Distinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1159/000348634
Description	ANCA-associated vasculitis (AAV) is a potentially life-threatening disease with frequent and often severe kidney involvement which may result in end-stage renal disease. Anti-PR3 and anti-MPO disease are genetically distinct diseases and may have a different pathogenesis. Recent discovery of new autoantibodies (anti-LAMP-2) and the role of complement activation in the pathogenesis of AAV could result in better monitoring of the activity of the disease and identification of new treatment targets. The outcome of patients with AAV has dramatically improved, but long-term mortality still remains relatively high partly due to effective but relatively toxic immunosuppressive treatment. Recent studies demonstrated that B-cell depletion with rituximab is comparable to cyclophosphamide as induction treatment in newly diagnosed AAV patients and better than cyclophosphamide in relapsing patients. Rituximab-based maintenance treatment is superior to standard treatment with azathioprine. The use of more targeted treatment will hopefully be translated into a better long-term outcome of AAV patients. ANCA-associated vasculitis (AAV) is a potentially life-threatening disease with frequent and often severe kidney involvement which may result in end-stage renal disease. Anti-PR3 and anti-MPO disease are genetically distinct diseases and may have a different pathogenesis. Recent discovery of new autoantibodies (anti-LAMP-2) and the role of complement activation in the pathogenesis of AAV could result in better monitoring of the activity of the disease and identification of new treatment targets. The outcome of patients with AAV has dramatically improved, but long-term mortality still remains relatively high partly due to effective but relatively toxic immunosuppressive treatment. Recent studies demonstrated that B-cell depletion with rituximab is comparable to cyclophosphamide as induction treatment in newly diagnosed AAV patients and better than cyclophosphamide in relapsing patients. Rituximab-based maintenance treatment is superior to standard treatment with azathioprine. The use of more targeted treatment will hopefully be translated into a better long-term outcome of AAV patients. (en)
Title	ANCA-Associated Renal Vasculitis - An Update ANCA-Associated Renal Vasculitis - An Update (en)
skos:prefLabel	ANCA-Associated Renal Vasculitis - An Update ANCA-Associated Renal Vasculitis - An Update (en)
skos:notation	RIV/00064165:_____/13:10173697!RIV14-MZ0-00064165
http://linked.open...avai/predkladatel	Všeobecná fakultní nemocnice v Praze
http://linked.open...avai/riv/aktivita	I V
http://linked.open...avai/riv/aktivity	I, V
http://linked.open...iv/cisloPeriodika	2013
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Hrušková, Zdenka Tesař, Vladimír
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Všeobecná fakultní nemocnice v Praze / (nerozlišená součást)
http://linked.open...dnocenehoVysledku	61222
http://linked.open...ai/riv/idVysledku	RIV/00064165:_____/13:10173697
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	randomized-trial; wegeners-granulomatosis; term-follow-up; daily oral cyclophosphamide; refractory granulomatous manifestations; small-vessel vasculitis; antineutrophil cytoplasmic autoantibodies; antibody-associated vasculitis (en)
http://linked.open.../riv/klicoveSlovo	term-follow-up antibody-associated vasculitis antineutrophil cytoplasmic autoantibodies daily oral cyclophosphamide refractory granulomatous manifestations small-vessel vasculitis wegeners-granulomatosis randomized-trial
http://linked.open...odStatuVydavatele	CH - Švýcarská konfederace
http://linked.open...ontrolniKodProRIV	[F7A071486C93]
http://linked.open...i/riv/nazevZdroje	Contributions to Nephrology
http://linked.open...in/vavai/riv/obor	FE
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	2 (xsd:int)
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	181
http://linked.open...iv/tvurceVysledku	Hrušková, Zdenka Tesař, Vladimír
http://linked.open...ain/vavai/riv/wos	000322846600023
issn	0302-5144
number of pages	13 (xsd:int)
http://bibframe.org/vocab/doi	10.1159/000348634

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 85 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software